Peptides CDMO AmbioPharm, has broken ground on a 650 m², $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.

Building 2, as it is called will feature advanced fragment-based peptide synthesis with multiple 1,000-3,000L solid- and liquid-phase lines. The output will be further processed using existing downstream purification and isolation capabilities at the company’s sites in North Augusta, South Carolina, and Shanghai itself.

CDMO SK Pharmteco has announced plans to invest $260 million in a new small molecule and peptide facility in Sejong, South Korea, the fifth in its home country and the cornerstone of its global manufacturing network. This is scheduled to begin operations in late 2026, creating over 300 jobs.

CordenPharma is to spend about €900 million over the next three years to expand its peptide technology platform, with investments on both sides of the Atlantic. This will be the largest strategic investment to date for the company, which is owned by pan-European private equity firm Astorg and aims to achieve €1 billion/year in sales from peptides

India’s PI Industries has agreed to acquire UK-based Plant Health Care (PHC), a specialist in protein and peptide technology for agricultural applications, for £32 million. This is subject to a UK court process, which, among other things, requires approval by shareholders holding at least 75% of the shares. It is expected to be completed by Q2 of the 2025 fiscal year.

Almac Group has announced the completion of two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland. The total investment is about $400 million and is part of a global investment programme announced in June 2022.

One is a 2,600 m² GMP facility that more than doubles peptide API manufacturing capacity. This “will enhance synthesis, purification and isolation capabilities and meet anticipated demand for clinical development and commercial products”, the company said.

CordenPharma has announced the commissioning of new GMP capacities at its Frankfurt site to manufacture early clinical phase peptide APIs. The investment is still being finalised, but will be fully operational in Q2 and authorised by German authorities in 2H.

In response to growing demand worldwide, WuXi AppTec has commissioned two new peptide plants, one each at its Changzhou and Taixing sites in China. Both use digital operation systems with automated solvent delivery, in order to optimise production consistency, minimise human errors and reduce production cycle time.

This investment will increase the company’s total solid-phase peptide synthesis (SPPS) reactor volume to 32,000 litres. It also marks the official launch of Taixing as WuXi AppTec’s fifth API production sites.